BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

911 related articles for article (PubMed ID: 8345076)

  • 1. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.
    Gemzell-Danielsson K; Swahn ML; Svalander P; Bygdeman M
    Hum Reprod; 1993 Jun; 8(6):870-3. PubMed ID: 8345076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of RU 486.
    Bygdeman M; Swahn ML; Gemzell-Danielsson K; Svalander P
    Ann Med; 1993 Feb; 25(1):61-4. PubMed ID: 8435191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a single post-ovulatory dose of RU486 on endometrial maturation in the implantation phase.
    Gemzell-Danielsson K; Svalander P; Swahn ML; Johannisson E; Bygdeman M
    Hum Reprod; 1994 Dec; 9(12):2398-404. PubMed ID: 7714164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation.
    Cameron ST; Critchley HO; Buckley CH; Kelly RW; Baird DT
    Fertil Steril; 1997 Jun; 67(6):1046-53. PubMed ID: 9176442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.
    Swahn ML; Johannisson E; Daniore V; de la Torre B; Bygdeman M
    Hum Reprod; 1988 Oct; 3(7):915-21. PubMed ID: 2846630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
    Greene KE; Kettel LM; Yen SS
    Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy.
    Batista MC; Cartledge TP; Zellmer AW; Merino MJ; Axiotis C; Loriaux DL; Nieman LK
    Am J Obstet Gynecol; 1992 Jul; 167(1):60-5. PubMed ID: 1442957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
    Cameron ST; Thong KJ; Baird DT
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.
    Schaison G; George M; Lestrat N; Reinberg A; Baulieu EE
    J Clin Endocrinol Metab; 1985 Sep; 61(3):484-9. PubMed ID: 2991322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ovulation by low-dose mifepristone (RU 486).
    Ledger WL; Sweeting VM; Hillier H; Baird DT
    Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term low-dose mifepristone on reproductive function in women.
    Croxatto HB; Kovács L; Massai R; Resch BA; Fuentealba B; Salvatierra AM; Croxatto HD; Zalányi S; Viski S; Krenács L
    Hum Reprod; 1998 Apr; 13(4):793-8. PubMed ID: 9619526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium.
    Swahn ML; Bygdeman M; Cekan S; Xing S; Masironi B; Johannisson E
    Hum Reprod; 1990 May; 5(4):402-8. PubMed ID: 2113927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contraceptive efficacy of low doses of mifepristone.
    Marions L; Danielsson KG; Swahn ML; Bygdeman M
    Fertil Steril; 1998 Nov; 70(5):813-6. PubMed ID: 9806558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of anti-progesterones as a medical IUD.
    Nieman LK; Loriaux DL
    Baillieres Clin Obstet Gynaecol; 1988 Sep; 2(3):609-16. PubMed ID: 3233821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F2 alpha concentrations.
    Gemzell-Danielsson K; Hamberg M
    Hum Reprod; 1994 Sep; 9(9):1626-30. PubMed ID: 7836511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.